Hanger Inc

Hanger — Investor Presentation (August 2013)

24 slides from Hanger's investor presentation, Aug 21, 2013

  1. Slide 1: 150 Years of Empowering Human Potential - Investor Presentation

    150 YEARS Investor Presentation of Empowering Human Potential. August 2013

  2. Slide 2: Safe Harbor

    SAFE HARBOR Except for the historical information contained herein, the matters discussed in this presentation constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. These include, but are not limited to,

  3. Slide 3: Vision

    VISION Be the partner of choice for products and services that enhance human physical capability.

  4. Slide 4: Overview

    OVERVIEW • LTM net sales of $1.0 billion • 2012 adjusted EBITDA* of $166 million • 2012 adjusted EPS* of $1.80 • Market capitalization of $1.1 billion • Two segments: – Patient Care – 83% of sales – Products & Services – 17% of sales $760.1 $817.4 $918.5 $985.6 2009 2010 2011 2012 CAGR 9.0%Growth in

  5. Slide 5: Key Investment Points

    KEY INVESTMENT POINTS • Compelling O&P industry growth dynamics • Market leader in O&P patient care • Proven organic growth and acquisition capabilities • Solid financial position • Steady margin enhancement • Growth opportunities in adjacent markets

  6. Slide 6: Patient Care Profile

    PATIENT CARE • Over 740 O&P patient-care centers in 45 states • Over 1,300 O&P certified and licensed clinicians • Treat more than 1,000,000 patients annually • Stand alone design, fabricate and fit • Delivery through clinics, hospitals and physician offices • Network management capability provides

  7. Slide 7: Patient Care Market Position

    PATIENT CARE Hanger 20% MARKET POSITION • Only national or regional provider • No other provider has more than 2% market share $4.3 Billion Total Addressable Market

  8. Slide 8: Consistent Organic and Acquisition Growth

    PATIENT CARE 4.9% 4.6% 2.6% 4.0% 3.2% 2.0% 2.8% 4.0% 2009 2010 2011 2012 Same Center Acquisitions/Other 8.1% 6.6% 5.4% 8.0% CONSISTENT ORGANIC AND ACQUISITION GROWTH 5% - 8% Range

  9. Slide 9: Patient Care Reimbursement Sources

    PATIENT CARE REIMBURSEMENT SOURCES Commercial and other 59% Medicare 29% Medicaid 6% VA 6% Commercial – 59% • 1-3 year contracts • Scale and capabilities are competitive advantage Government – 41% • O&P is a very small part of trillion dollar healthcare spending • Exempt from MDET and competitive bi

  10. Slide 10: Compelling Growth Drivers

    COMPELLING GROWTH DRIVERS • Disease and aging population • Advancing technology • Regulatory and healthcare reform • Increased focus on costs and outcomes 12.4% 12.7% 13.0% 16.1% 19.3% 2000 2008 2010 2020 2030 65+ 2.6% 10.8% 23.1% 20-39 40-59 60+ Sources: Company estimates; Wall Street Research; 200

  11. Slide 11: Patient Care Growth Opportunities

    PATIENT CARE • First to market with new technologies and products • Linkia Network Management • Diversification into new adjacent businesses • O&P acquisitions • Sales synergies across businesses • Changing healthcare environment GROWTH OPPORTUNITIES

  12. Slide 12: Products & Services

    PRODUCTS & SERVICES

  13. Slide 13: Products & Services Profile

    PRODUCT & SERVICES Distribution: • Largest dedicated distributor of O&P devices and components • Over 33,000 O&P related items • 6 strategically located distribution facilities • Manufacture and distribute therapeutic footwear • Development and commercialization of new products Rehabilitative Soluti

  14. Slide 14: Products & Services Opportunities

    PRODUCT & SERVICES • Increase value proposition of product line • Increase penetration of existing customer base • Expand market presence geographically • Expand into new channels • Leverage product development and distribution capabilities • Expand O&P fabrication operation to Independent O&P Provi

  15. Slide 15: Financial Overview

    FINANCIAL OVERVIEW

  16. Slide 16: Solid Performance and Stability

    SOLID PERFORMANCE AND STABILITY • Earnings and margin growth • Substantial cash flow generation • Strong balance sheet management • Moderate leverage • Consistent reduction of leverage

  17. Slide 17: Leveraging Revenue Growth

    LEVERAGING REVENUE GROWTH $760.1 $817.4 $918.5 $985.6 2009 2010 2011 2012 CAGR 9.0% ($ in millions) 14.1% 14.8% 16.2% 16.8% Net Sales Adjusted EBITDA Margin* * Reconciliation to GAAP provided on slides 23 and 24

  18. Slide 18: Growth in Adjusted Diluted EPS

    GROWTH IN ADJUSTED DILUTED EPS* $1.13 $1.34 $1.57 $1.80 2009 2010 2011 2012 CAGR 16.8% Reconciliation to GAAP provided on slides 23 and 24

  19. Slide 19: Steady Comparable Quarter Growth

    STEADY COMPARABLE QUARTER GROWTH $0.10 $0.20 $0.30 $0.40 $0.50 $0.60 Q1 Q2 Q3 Q4 $15 $2 5 $35 $45 $55 Q1 Q2 Q3 Q4 2011 2012 2013 Adjusted EBITDA* ($ in millions) Revenues ($ in millions) Adjusted Earnings Per Diluted Share* $155 $175 $195 $215 $235 $255 $275 Q1 Q2 Q3 Q4 * Reconciliation to GAAP prov

  20. Slide 20: Solid Cash Flow and Balance Sheet

    SOLID CASH FLOW AND BALANCE SHEET $53 $72 $54 $62 $81 2008 2009 2010 2011 2012 ACP Acquisition 3.6 2.8 3.3 2.8 3.0 Operating Cash Flow Leverage Ratio* ($ in millions) * Reconciliation to GAAP provided on slides 23 and 24

  21. Slide 21: Key Investment Points

    KEY INVESTMENT POINTS • Compelling O&P industry growth dynamics • Market leader in O&P patient care • Proven organic growth and acquisition capabilities • Solid financial position • Steady margin enhancement • Growth opportunities in adjacent markets

  22. Slide 22: Appendix

    150 YEARS Appendix of Empowering Human Potential.

  23. Slide 23: Reconciliation of Non-GAAP Financial Measures

    RECONCILIATION OF NON- GAAP FINANCIAL MEASURES Dollars in millions, except per share data 2009 2010 2011 2012 Adjusted EBITDA Reconciliation Income from Operations $ 90.5 $ 80.5 $ 116.0 $ 129.3 Depreciation & Amortization $ 16.3 $ 18.8 $ 31.0 $ 34.7 Relocation expenses - $ 16.4 $ 1.2 - Acquisition e

  24. Slide 24: Reconciliation of Non-GAAP Financial Measures (Quarterly)

    RECONCILIATION OF NON- GAAP FINANCIAL MEASURES Dollars in millions, except per share data 2011 2012 2013 2013 Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Adjusted EBITDA Reconciliation Income from Operations $ 19.3 $ 32.9 $ 31.2 $ 32.5 $ 116.0 $ 21.7 $ 35.7 $ 35.4 $ 36.5 $ 129.3 $ 22.7 $ 36.6 Depreciation &

Hanger — Investor Presentation (August 2013) on 6ix